System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Ken Kato is an expert in Oncology at National Cancer Center Hospital (Japan, Tokyo) (Japan). As of October 2026, ScienceLeadR ranks Ken Kato in the top 1% of experts worldwide for Esophageal Neoplasms, Esophageal Diseases and Gastrointestinal Neoplasms. Ken Kato has authored 779 publications, the most recent in 2026, and is an investigator in 23 clinical trials, 3 of them ongoing. SLR score: 3,204 (community average: 125). How the SLR is computed.

LeadR Profile

Ken Kato National Cancer Center Hospital (Japan, Tokyo) Japan
3 204 ScienceLeadR Reputation 3204

Unlock

Register Login
Network Map

Oncology

Subspecialties: Surgery - Gastroenterology - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2007 - 2026
Source: PubMed

National Cancer Center Hospital (Japan, Tokyo)

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 779

Citations

Citations: 25 078 1st author: 41 Last author: 117 Unique author: 4

Main journals

J Clin Oncol 191
Esophagus 43
Jpn J Clin Oncol 32
Cancer Sci 26
Ann Oncol 25

Best Journals

J Clin Oncol 129
Ann Oncol 9
Lancet Oncol 5

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Metastasis-directed local therapy and strategic de-escalation of systemic therapy for oligometastatic esophageal squamous cell carcinoma.
PMID 42747081 — radiotherapy, cells, carcinoma, squamous cell, neoplasms, drug therapy, immunotherapy, neoplasm metastasis, esophageal squamous cell carcinoma, therapeutics, esophageal neoplasms, chemotherapy		Jpn J Clin Oncol20260
Proteinuria as the cause of early dose modification in Japanese patients with metastatic colorectal cancer treated with fruquintinib: a multicenter real-world study.
PMID 42661135 — proteinuria, safety, neoplasms, therapeutics, colorectal neoplasms		Int J Clin Oncol20260
Institutional enrollment volume and clinical outcomes after surgery or chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma: a supplementary analysis of JCOG0502.
PMID 42658443 — cells, carcinoma, squamous cell, chemoradiotherapy, esophageal squamous cell carcinoma, ischemia		Esophagus20260
An integrated individual patient-level database from JCOG trials in esophageal cancer: A research platform (JCOG2512A).
PMID 42531880 — neoplasms, research, therapeutics, esophageal neoplasms		Eur J Surg Oncol20260
Squamous cell carcinoma antigen and carcinoembryonic antigen monitoring during post-definitive chemoradiotherapy surveillance for esophageal squamous cell carcinoma: JCOG2106A.
PMID 42442351 — cells, research design, esophageal diseases, carcinoma, squamous cell, carcinoembryonic antigen, chemoradiotherapy, esophageal squamous cell carcinoma		Dis Esophagus20260

Clinical Studies 23

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2 Study Chair: 2

By phase:

Phase 3 13
Phase 1 4
Phase 2 3
N/A 1
Phase 1/Phase 2 1
Phase 2/Phase 3 1

By status:

Completed 16
Recruiting 3
Active not recruiting 2
Terminated 1
Unknown 1

By type:

Interventional 22
Observational 1

By Monocentric/Multicentric:

monocentric 8
multicentric2to4 1
multicentric5to9 1
multicentricup10 13

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Perioperative HLX10 (Serplulimab) With S 1 Oxaliplatin (SOX) in Locally Advanced and PD L1 Positive Gastric or Esophagogastric Junction Adenocarcinoma
NCT07699939 — tegafur, esophagogastric junction, adenocarcinoma, drug therapy, oxaliplatin, therapeutics, oxonic acid, chemotherapy		Phase 2Recruiting2026
Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum based Combination Therapy
NCT07347314 — cells, safety, pharmaceutical preparations, neoplasms, adenocarcinoma, disease progression, multiple chronic conditions, drug therapy, research, therapeutics, chemotherapy, carcinoma		Phase 2Recruiting2025
Anti CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE CRC 01)
NCT05464030 — leucovorin, pharmaceutical preparations, neoplasms, bevacizumab, fluorouracil, maximum tolerated dose, colorectal neoplasms, capecitabine		Phase 1Active not recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS